GB : Sensyne Health - Becoming a major US player

Sensyne has announced another major deal with a US health system following last Friday's update. It has signed a strategic research agreement (SRA) with the Colorado Center for Personalized Medicine (CCPM). The deal is enormous covering 7.3m patients which adds to the 2.5m dataset covered from the St Luke's deal announced on Friday. In addition it brings significant amounts of genomic data which is highly incremental to Sensyne. This deal means that Sensyne has now reached its end of 2022 dataset target (>17.5m patient records) and has the scale to be a major player in the US.

Most Viewed See latest

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers